Cipla to enter Brazil, China with emerging market focus
Friday, February 24, 2017, 12:56 PM
India’s second largest drug maker by revenue, Cipla, is entering the Brazil and Chinese markets, to grow its emerging markets (EMs) portfolio. Cipla is also looking at further acquisitions, to grow its speciality business in the US. Cipla's focus in China, will be on respiratory products. In Brazil, the plan is to launch oncology products.